This study involves women with high risk locally advanced cervix cancer, which means the cancer has grown beyond the cervix into nearby tissues but has not spread to distant parts of the body. High risk refers to cases where the cancer is more likely to come back after standard treatment or may not respond as well to usual therapy. The study will use two medications: Keytruda, which contains pembrolizumab, and Lenvatinib. Pembrolizumab works by helping the body’s immune system recognize and fight cancer cells, while Lenvatinib is a tyrosine kinase inhibitor that blocks signals cancer cells need to grow and blocks the formation of new blood vessels that tumors need to survive. The purpose of the study is to see how well these treatments work together in preventing the cancer from getting worse or coming back within 24 months after treatment.

Women in this study will first receive standard treatment for their cancer, which includes chemoradiation, a combination of chemotherapy and radiation therapy, along with brachytherapy, a type of internal radiation treatment where the radiation source is placed directly inside or very close to the cancer. During this standard treatment, participants will also begin receiving Keytruda through an intravenous infusion, which means the medication is given directly into a vein. After completing the radiation treatments, there will be an eight-week waiting period to allow the body to recover.

Following the eight-week recovery period, participants will continue receiving Keytruda infusions and will also start taking Lenvatinib capsules by mouth, which means the medication is taken orally. Treatment with Keytruda can continue for up to 24 months, while Lenvatinib can be given for up to 12 months. Throughout the study, doctors will monitor how well the cancer responds to treatment and whether it grows or spreads. The study will track participants to measure the time period during which the cancer does not get worse, which doctors call progression free survival.